Trade Summary

5 days ago, Henneman John B III, serving as Dir at Anika Therapeutics, Inc. (ANIK), purchased 5,000 shares at $14.66 per share, for a total transaction value of $73,320.00. Following this transaction, Henneman John B III now holds 54,871 shares of ANIK.

This purchase represents a 10.00% increase in Henneman John B III's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, May 1, 2026 and publicly disclosed via SEC Form 4 filing on Monday, May 4, 2026, 3 days after the trade was made.

Anika Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.